{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T02:01:20Z","timestamp":1788141680240,"version":"build-2803163510"},"reference-count":10,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2017,5,1]],"date-time":"2017-05-01T00:00:00Z","timestamp":1493596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","transplantation-proceedings.org","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation Proceedings"],"published-print":{"date-parts":[[2017,5]]},"DOI":"10.1016\/j.transproceed.2017.01.075","type":"journal-article","created":{"date-parts":[[2017,4,27]],"date-time":"2017-04-27T07:18:02Z","timestamp":1493277482000},"page":"813-816","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Spironolactone in Post-Transplant Proteinuria: A Safe Alternative Therapy"],"prefix":"10.1016","volume":"49","author":[{"given":"M.V.","family":"de Sousa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.P.","family":"Guida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.F.","family":"do Valle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.F.","family":"Camargo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.G.","family":"Rivelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Mazzali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.transproceed.2017.01.075_bib1","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1681\/ASN.2007101079","article-title":"The aggravating mechanisms of aldosterone on kidney fibrosis","volume":"19","author":"Remuzzi","year":"2008","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.transproceed.2017.01.075_bib2","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1038\/nrneph.2013.110","article-title":"Contribution of aldosterone to cardiovascular and renal inflammation and fibrosis","volume":"9","author":"Brown","year":"2013","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.transproceed.2017.01.075_bib3","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1053\/j.ajkd.2011.03.029","article-title":"Aldosterone-induced fibrosis in the kidney: questions and controversies","volume":"58","author":"Brem","year":"2011","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.transproceed.2017.01.075_bib4","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1159\/000339649","article-title":"Mineralocorticoid receptor antagonism and aldosterone synthesis inhibition do not improve glomerulosclerosis and renal interstitial fibrosis in a model of chronic kidney allograft injury","volume":"35","author":"Lahmer","year":"2011","journal-title":"Kidney Blood Press Res"},{"key":"10.1016\/j.transproceed.2017.01.075_bib5","first-page":"116","article-title":"Significance of urine diagnostic tests after renal transplantation","volume":"37","author":"Jenni","year":"2013","journal-title":"Transplantation"},{"key":"10.1016\/j.transproceed.2017.01.075_bib6","doi-asserted-by":"publisher","first-page":"1786","DOI":"10.2215\/CJN.01310211","article-title":"Posttransplantation proteinuria: an approach to diagnosis and management","volume":"6","author":"Shamseddin","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.transproceed.2017.01.075_bib7","doi-asserted-by":"publisher","first-page":"F1072","DOI":"10.1152\/ajprenal.90643.2008","article-title":"Spironolactone ameliorates transplant vasculopathy in renal chronic transplant dysfunction in rats","volume":"296","author":"Waanders","year":"2009","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.transproceed.2017.01.075_bib8","doi-asserted-by":"publisher","first-page":"2899","DOI":"10.1016\/j.transproceed.2010.08.024","article-title":"Addition of spironolactone to dual blockade of renin angiotensin system dramatically reduces severe proteinuria in renal transplant patients: an uncontrolled pilot study at 6 months","volume":"42","author":"Gonz\u00e1lez Monte","year":"2010","journal-title":"Transplant Proc"},{"key":"10.1016\/j.transproceed.2017.01.075_bib9","first-page":"1","article-title":"Aldosterone antagonists for preventing the progression of chronic kidney disease","volume":"29","author":"Bolignano","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.transproceed.2017.01.075_bib10","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1159\/000355736","article-title":"Esplerenone-mediated aldosterone blockade prevents renal fibrosis by reducing renal inflammation, interstitial cell proliferation and oxidative stress","volume":"37","author":"Chen","year":"2013","journal-title":"Kidney Blood Press Res"}],"container-title":["Transplantation Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041134517300891?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041134517300891?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,2]],"date-time":"2018-09-02T05:26:59Z","timestamp":1535866019000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0041134517300891"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5]]},"references-count":10,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017,5]]}},"alternative-id":["S0041134517300891"],"URL":"https:\/\/doi.org\/10.1016\/j.transproceed.2017.01.075","relation":{},"ISSN":["0041-1345"],"issn-type":[{"value":"0041-1345","type":"print"}],"subject":[],"published":{"date-parts":[[2017,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Spironolactone in Post-Transplant Proteinuria: A Safe Alternative Therapy","name":"articletitle","label":"Article Title"},{"value":"Transplantation Proceedings","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.transproceed.2017.01.075","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}